studies

la/mBC - HR-positive - 1st line (L1), dalotuzumab plus ridaforolimus plus exemestane vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsMK-8669-064, 2017 1.18 [0.81; 1.72] 1.18[0.81; 1.72]MK-8669-064, 201710%80NAnot evaluable objective responses (ORR)detailed resultsMK-8669-064, 2017 0.53 [0.17; 1.63] 0.53[0.17; 1.63]MK-8669-064, 201710%80NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-09 23:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 1441